GlobalData on MSN
MSD receives FDA approval for Winrevair’s updated indication
MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for ...
The FDA approved a label update for Winrevair to include that it lowers the risk for clinical worsening events in adults with ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...
4d
Does FDA’s Broader WINREVAIR Approval Strengthen Merck’s (MRK) Cardio-Pulmonary Pipeline Narrative?
On October 27, 2025, Merck announced that the FDA approved an expanded label for WINREVAIR (sotatercept-csrk), allowing its ...
More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...
The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...
The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...
Rahway, New Jersey Tuesday, October 28, 2025, 12:00 Hrs [IST] ...
Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...
Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback